Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06397573
Other study ID # 2023-CHU-001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 5, 2024
Est. completion date June 2027

Study information

Verified date May 2024
Source Baptist Health South Florida
Contact Michael Chuong, M.D.
Phone (786) 596-2000
Email MichaelChu@baptisthealth.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research study will enroll people who have cancer in their abdomen or pelvis that was treated previously with radiation therapy. The purpose of this research study is to test the safety and possible harms of treating tumors in these regions with another round of radiation therapy, called reirradiation or "reRT." The researchers want to find out what effects (good and bad) reRT has in people with cancer in the abdomen and pelvis.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date June 2027
Est. primary completion date June 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - A primary or metastatic lesion in the abdomen or pelvis for which reirradiation will be delivered. There is no maximum lesion size. - Single course of prior radiation therapy with prescribed equivalent dose in 2 Gy fractions (EDQ210) of at least 40 Gy. - 50% isodose line of the prior radiation therapy course is expected to overlap at minimum the 50% isodose line of the radiation therapy delivered in this study. - At least 6 months from completion of prior radiation therapy to initiation of study therapy. - Eastern Cooperative Oncology Group (ECOG) performance status 0-2. - Life expectancy at least 6 months. - Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Abstinence is acceptable if it is the participant's preferred method. Should a participant become pregnant or suspect pregnancy while participating in this study, the treating physician must be informed immediately. - Concurrent hormonal therapy or immunotherapy such as immune checkpoint inhibitor is allowed Exclusion Criteria: - Contraindication to having an MRI scan. - Lesion that would receive study therapy arises from or invades a gastrointestinal (GI) luminal organ (a lesion abutting but not invading a GI luminal organ is permitted) - Lesion that would receive study therapy is not located in the abdomen or pelvis. - > 1 course of overlapping radiation therapy delivered to the abdomen or pelvis. - < 70% of the gross tumor volume (GTV) receives at least the 95% of the prescribed dose on the original plan using the simulation day anatomy. - More than 1 lesion in the abdomen or pelvis that requires reirradiation. - History of inflammatory bowel disease. - Unable to acquire DICOM radiation therapy treatment plan from the prior radiation therapy. - Uncontrolled brain metastases, spinal cord compression, or leptomeningeal carcinomatosis. - Unresolved grade 2+ toxicity (Common Terminology Criteria for Adverse Events version 5.0) from previous anti-cancer therapy. - Any condition in the opinion of the investigator that would interfere with evaluation of study treatment or interpretation of participant safety or study results. - Individuals who are pregnant. - Chemotherapy given within 1 week prior to or following reirradiation. - Vascular endothelial growth factor (VEGF) inhibitor given within 8 weeks prior to or following reirradiation

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Reirradiation
Ablative reirradiation of 50 Gy in 5 fractions (5 sessions) that will occur once per day, either for 5 days in a row, or every other day.

Locations

Country Name City State
United States Miami Cancer Institute at Baptist Health South Florida Miami Florida

Sponsors (2)

Lead Sponsor Collaborator
Baptist Health South Florida Baptist Health Foundation

Country where clinical trial is conducted

United States, 

References & Publications (7)

Abusaris H, Hoogeman M, Nuyttens JJ. Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region. Technol Cancer Res Treat. 2012 Dec;11(6):591-7. doi: 10.7785/tcrt.2012.500261. Epub 2012 May 7. — View Citation

Barsky AR, Reddy VK, Plastaras JP, Ben-Josef E, Metz JM, Wojcieszynski AP. Proton beam re-irradiation for gastrointestinal malignancies: a systematic review. J Gastrointest Oncol. 2020 Feb;11(1):187-202. doi: 10.21037/jgo.2019.09.03. — View Citation

Hunt A, Das P, Minsky BD, Koay EJ, Krishnan S, Herman JM, Taniguchi C, Koong A, Smith GL, Holliday EB. Hyperfractionated abdominal reirradiation for gastrointestinal malignancies. Radiat Oncol. 2018 Aug 7;13(1):143. doi: 10.1186/s13014-018-1084-0. — View Citation

Moningi S, Ludmir EB, Polamraju P, Williamson T, Melkun MM, Herman JD, Krishnan S, Koay EJ, Koong AC, Minsky BD, Smith GL, Taniguchi C, Das P, Holliday EB. Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies. Clin Transl Radiat Oncol. 2019 Aug 27;19:59-65. doi: 10.1016/j.ctro.2019.08.004. eCollection 2019 Nov. — View Citation

Munoz F, Fiorica F, Caravatta L, Rosa C, Ferella L, Boldrini L, Fionda B, Alitto AR, Nardangeli A, Dionisi F, Arcangeli S, Di Marzo A, Pontoriero A, Donato V, Massaccesi M. Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Cancer Treat Rev. 2021 Apr;95:102176. doi: 10.1016/j.ctrv.2021.102176. Epub 2021 Mar 8. — View Citation

Sadozye AH. Re-irradiation in Gynaecological Malignancies: A Review. Clin Oncol (R Coll Radiol). 2018 Feb;30(2):110-115. doi: 10.1016/j.clon.2017.11.013. Epub 2017 Dec 9. — View Citation

Tao R, Tsai CJ, Jensen G, Eng C, Kopetz S, Overman MJ, Skibber JM, Rodriguez-Bigas M, Chang GJ, You YN, Bednarski BK, Minsky BD, Delclos ME, Koay E, Krishnan S, Crane CH, Das P. Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol. 2017 Jan;122(1):146-151. doi: 10.1016/j.radonc.2016.12.015. Epub 2017 Jan 3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Grade 3 or higher acute toxicity Number of participants who experience Grade 3 or higher acute toxicity [graded per Common Terminology Criteria for Adverse Events (CTCAE)] possibly, probably, or definitely related to reRT. 1 year
Primary Grade 5 toxicity Number of participants who experience Grade 5 toxicity (graded per CTCAE) possibly, probably, or definitely related to reRT. 1 year
Secondary Freedom from local progression (FFLP) FFLP is defined as the duration of time from baseline to progressive disease (PD) in the re-irradiated lesion or death of any cause, whichever occurs first. Response to treatment will be assessed using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). 1 year
Secondary Overall survival (OS) OS is defined as the defined as the duration of time from baseline to death of any cause, or date of last follow-up, whichever occurs first. 1 year
Secondary Grade 3 or higher late toxicity Number of participants who experience Grade 3 or higher acute toxicity [graded per Common Terminology Criteria for Adverse Events (CTCAE)] possibly, probably, or definitely related to reRT that occurs at least 90 days after reRT therapy has ended. 1 year
Secondary Quality of life (QOL) QOL will be assessed using the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire. The FACT-G is a 27-item questionnaire measuring physical, social, emotional, and functional well-being. All questions in the FACT-G use a 5-point rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much), with a possible range of 0-108 points. Negatively worded items are reverse scored prior to summing so that higher scores indicate better QOL. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT03144622 - 18F-FSPG PET/CT Imaging in Patients With Cancers
Completed NCT04553471 - Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers N/A
Completed NCT02566096 - Efficacy of Transverses Abdominis -Plane Block With Bupivacaine Versus Bupivacaine With Morphine Postoperatively Phase 4
Recruiting NCT05533424 - Ultrasound Guided Quadratus Lumborum Block Versus Transversus Abdominis Plane Block as Postoperative Analgesia in Patients Undergoing Abdominal Cancer Surgery. Phase 3
Completed NCT04729634 - Survey Of Mobilisation and Breathing Exercises After Thoracic and Abdominal Surgery N/A
Recruiting NCT00493688 - A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Completed NCT04152564 - Cardio-pulmonary and Analgesic Effects of Pre-peritoneal VS Epidural Infusion of L-bupivacaine on Abd. Cancer Patients N/A
Completed NCT03555266 - NSS-2 BRIDGE Device in Post-Operative Pain Management N/A
Withdrawn NCT04114422 - A Seven-day Preoperative Exercise Training Program in People With Abdominal Cancer N/A
Terminated NCT04199754 - IV Contrast-Enhanced Cone Beam Computed Tomography (CBCT) in Radiotherapy Early Phase 1
Recruiting NCT03063112 - Radiofrequency and Chemical Neurolysis of Thoracic Splanchnic Nerve for Abdominal Cancer Pain N/A
Completed NCT02998736 - Trial of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy Phase 1
Completed NCT00780611 - Investigating the Improvement in 4D CT Images Using AV Biofeedback
Completed NCT00415675 - Respiratory Tumor and Normal Tissue Motion N/A
Not yet recruiting NCT05903430 - A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
Completed NCT03751384 - Improvement of Compliance for High Doses of EPA Amongst Patients With Colorectal Cancer N/A
Recruiting NCT05219058 - Reconstruction in Extended MArgin Cancer Surgery
Completed NCT03102619 - Wireless Assessment of Respiratory and Circulatory Distress; A Pilot Study N/A
Not yet recruiting NCT06265948 - Comparsion Between Intravenous Infusion of Ketofol and Inhalational Anasthetics in Abdominal Cancer Surgeries for Post Operative Analgesia
Completed NCT05524454 - Evaluation of a Cone-beam CT Scanner for Image Guided Radiotherapy N/A

External Links